Composition for improving menstrual complaints, depression, decreased concentration, decreased motivation for social and everyday activities, autonomic nerve disorders, pain, control, and decreased sleep quality

The Apocynum venetum L. leaf extract composition effectively addresses women's menstrual-related complaints by providing stress relief, improved sleep, and reduced symptoms, enhancing their quality of life and workforce participation.

WO2025009025A1PCT designated stage expired Publication Date: 2025-01-09TOKIWA PHYTOCHEM CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2023/024654
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-07-03
Publication Date
2025-01-09

AI Technical Summary

Technical Problem

Women's participation in the workforce is hindered by irregular complaints associated with menstruation, including depressed mood, decreased concentration, decreased desire to socialize, autonomic nerve disturbances, pain, and decreased sleep quality, which are not effectively addressed by existing solutions.

Method used

A composition containing Apocynum venetum L. leaf extract, which acts as an agonist for GABA receptors, is used to alleviate these symptoms, providing stress-reducing, relaxing, and sleep-improving effects, and is formulated into various forms such as food, medicine, or cosmetics, with a preferred dosage of 30 mg to 150 mg per day.

Benefits of technology

The composition significantly improves irregular complaints, depressed mood, concentration loss, decreased motivation, autonomic nerve disturbances, pain, and sleep quality in healthy adult women, as demonstrated by clinical trials showing improved scores on symptom questionnaires and sleep evaluations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JPOXMLDOC01-APPB-T000001
    Figure JPOXMLDOC01-APPB-T000001
  • Figure JPOXMLDOC01-APPB-T000002
    Figure JPOXMLDOC01-APPB-T000002
  • Figure JPOXMLDOC01-APPB-T000003
    Figure JPOXMLDOC01-APPB-T000003
Patent Text Reader

Abstract

Provided is a composition that has the effect of improving menstrual complaints, depression, decreased concentration, decreased motivation for social and everyday activities, autonomic nerve disorders, pain, control, and decreased sleep quality. The present invention is a composition containing rafuma leaf extract that has the effect of improving menstrual complaints, depression, decreased concentration, decreased motivation for social and everyday activities, autonomic nerve disorders, pain, control, and decreased sleep quality.
Need to check novelty before this filing date? Find Prior Art

Description

A composition that improves menstrual symptoms, depression, difficulty concentrating, decreased motivation to socialize and engage in daily activities, autonomic nervous system disorders, pain, control, and poor sleep quality.

[0001] The present invention relates to a composition that improves menstrual symptoms such as depression, poor concentration, decreased motivation to socialize and participate in daily activities, autonomic nervous system disturbances, pain, control, and poor sleep quality.

[0002] In recent years, the decline in the working population due to an aging society and a declining birthrate has become a serious issue, spurring calls for increased female labor force participation. However, it has been pointed out that women's unique issues, such as menstrual discomfort caused by hormonal changes, premenstrual syndrome, and menopausal symptoms, hinder women's active participation. Providing appropriate support and measures to address these unique female issues is expected to improve women's health. Menstrual discomfort is thought to be related to fluctuations in female hormones. During the luteal phase after ovulation, estrogen (the follicle hormone) and progesterone (the luteal hormone) are secreted in large amounts. However, in the latter half of the luteal phase, the levels of follicle hormone and luteal hormone rapidly decline, disrupting the balance of hormones and neurotransmitters in the brain and thought to be the cause of menstrual discomfort. There are a variety of symptoms that accompany menstruation, including pain (abdominal pain, headache, back pain, fatigue), autonomic nervous system disorders (hot flashes, loss of appetite or overeating, dizziness), negative emotions (emotional instability, irritability, depression, anxiety), decreased concentration, water retention (swelling, abdominal distension, breast tenderness), and decreased quality of sleep.

[0003] On the other hand, Apocynum venetum L. is a perennial herb belonging to the Apocynaceae family that grows wild in temperate regions from China to Europe and Asia. Apocynum leaves are consumed as tea in China, and in Japan, they have been shown to lower blood pressure and are designated as a food for specified health uses.

[0004] Regarding the stress-reducing and relaxing effects of Rehmannia, animal studies have reported that Rehmannia leaf extract may exhibit antidepressant effects (Non-Patent Document 1, Patent Document 1) and anti-anxiety effects (Non-Patent Document 2). Furthermore, Rehmannia extract acts as an agonist of the GABA receptor, an inhibitory neurotransmitter in the brain, and clinical trials have shown that simultaneous daily intake of 25 mg of GABA and 25 mg of Rehmannia leaf extract reduced chromogranin A, an indicator of stress (Non-Patent Document 3, Patent Document 2).

[0005] In recent years, the sleep-improving effects of Rahuma leaves have also been attracting attention. In a clinical trial in which participants wore an electroencephalograph at night and used their brain waves to evaluate sleep, it was reported that Rahuma leaf extract increased the proportion of non-REM sleep, a type of deep sleep (Non-Patent Document 4). In another clinical trial, the OSA Sleep Questionnaire MA version was used to evaluate the perceived improvement in sleep, and significant improvements were observed in Factor II, which evaluates sleep onset and sleep maintenance, as well as in the improvement of resting effects and fatigue recovery (Non-Patent Document 5, Patent Document 3).

[0006] Butterweck V, Nishibe S, Sasaki T, Uchida M., “Antidepressant effects of apocynum venetum leaves in a forced swimming test.”, Biol Pharm Bull., 24(7), 848 - 851(2001). Grundmann O, Nakajima J, Kamata K, Seo S, Butterweck V., “Kaempferol from the leaves of Apocynum venetum possesses anxiolytic activities in the elevated plus maze test in mice.”, Phytomedicine, 16, 295 - 302(2009). YAMATSUTA A, YAMASHITA Y, MARU I, YANG J, TATSUSAKI J and KIM M., “The Improvement of Sleep by Oral Intake of GABA and Apocynum venetum Leaf Extract.”, JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY 61(2), 182 - 187(2015). Yamatsuta A, Yamashita Y, Maru I, Yang J, Tatsusaki J, Kim M., “The Improvement of Sleep by Oral Intake of GABA and Apocynum venetum Leaf Extract.”, J Nutr Sci Vitaminol (Tokyo), 61(2), 182 - 187(2015). Nakata A, Yamashita S, Suzuki N, Liang T, Kuniyoshi T, Yang J, Takara T, “Effect of an Apocynum venetum Leaf Extract(VENETRON(R)) on Sleep Quality and Psychological Stress Improvement - A Randomized, Double - blind,Placebo-controlled Crossover Study-. ”, Jpn Pharmacol Ther., 46(1), 117-125 (2018).

[0007] Japanese Patent No. 4629933 Japanese Patent Application Laid-Open No. 2011-93842 Japanese Patent No. 7099685

[0008] According to the 2018 Health Promotion Survey for Working Women conducted by the Health and Global Policy Institute, a nonprofit organization, 45% of respondents said they "did nothing" to deal with abnormal symptoms associated with menstruation. Therefore, consuming readily available, safe plant-derived ingredients is expected to greatly improve women's health. However, there are still few reported cases of plant-derived ingredients being used to treat premenstrual syndrome and premenstrual dysphoric disorder, or to alleviate menstrual complaints and other symptoms in healthy adult women with no history of the condition.

[0009] Furthermore, although Rhaematous root extract has stress-reducing, relaxation-enhancing, and sleep-improving effects, its effects on menstrual discomfort, sleep, and other symptoms in healthy adult women are unknown.

[0010] The inventors have conducted research into the above-mentioned problems using Rhaematous rhododendron leaf extract, and as a result have conducted clinical trials to verify the effects of extract on menstrual complaints, sleepiness, and other symptoms in healthy adult women who are undergoing treatment for premenstrual syndrome and premenstrual dysphoric disorder or who have no history of these conditions. The inventors have demonstrated for the first time the effectiveness of extract on menstrual complaints, sleepiness, and other symptoms, which led to the present invention.

[0011] That is, a composition for improving premenstrual and menstrual symptoms according to one aspect of the present invention contains a rahma leaf extract as an active ingredient.

[0012] Another aspect of the present invention provides a composition for improving decreased concentration before and during menstruation, which contains a rahma leaf extract as an active ingredient.

[0013] A composition for ameliorating premenstrual depression according to another aspect of the present invention contains a Rhaematous leaf extract as an active ingredient.

[0014] Another aspect of the present invention provides a composition for improving premenstrual decline in motivation to socialize and engage in daily activities, which contains an extract of Rhaematous rhododendron leaves as an active ingredient.

[0015] A composition for improving premenstrual autonomic nervous system disorders according to another aspect of the present invention contains an extract of Rhaematous rhododendron leaves as an active ingredient.

[0016] A composition for alleviating menstrual pain according to another aspect of the present invention contains an extract of Rhaematous leaves as an active ingredient.

[0017] A composition for improving menstrual control according to another aspect of the present invention contains an extract of Rhagma leaves as an active ingredient.

[0018] A composition for improving premenstrual sleep according to another aspect of the present invention contains an extract of Rhaematous rhododendron leaves as an active ingredient.

[0019] As described above, the present invention provides a composition that improves menstrual symptoms such as vague symptoms, depression, decreased concentration, decreased motivation for socializing and daily activities, autonomic nervous system disorders, pain, control, and decreased quality of sleep.

[0020] Hereinafter, embodiments of the present invention will be described in detail. However, the present invention can be embodied in many different forms and is not limited to the examples described in the following embodiments and examples.

[0021] One embodiment of the present invention is a composition that improves menstrual symptoms such as depression, poor concentration, decreased motivation to socialize and participate in daily activities, autonomic nervous system disturbances, pain, control, and poor sleep quality.

[0022] The Rahma leaf extract in the present invention includes an extract obtained by extracting and concentrating Rahma (scientific name: Apocynum venetum L.) leaves with a solvent containing at least one of water, ethanol, aqueous ethanol, and an organic solvent; an extract obtained by adsorbing the extract thus obtained onto at least one of acrylic, styrene, methacrylic, and aromatic synthetic adsorbents, and concentrating the fraction eluted with aqueous ethanol up to a concentration of 10 to 95%, and an extract obtained by drying the extract.

[0023] The composition may also be in the form of a food, medicine, or cosmetic, and in the case of a food, it may be in the form of a functional food or health food.Furthermore, in the case of a food, it may be in the form of not only a solid but also a beverage.

[0024] When the composition is a food, it may be in the form of, for example, a drink, candy, jelly, gummy or other desserts, and when it is a health food or a food with functional claims, it may be in the form of, for example, a tablet, hard capsule, soft capsule, granule, drink or the like.

[0025] Furthermore, when the composition is a pharmaceutical product, the pharmaceutical form may be a tablet, capsule, pill, liquid, or emulsion. The administration method is not particularly limited, but an orally administrable form is desirable. Furthermore, various carriers may be added within a pharmaceutically acceptable range. Examples of carriers include excipients, colorants, sweeteners, suspending agents, etc.

[0026] The content of the Rhafnia extract in the composition can be adjusted appropriately according to the expected intake amount.

[0027] Furthermore, in order to obtain the effect of this composition in improving menstrual symptoms such as vague symptoms, depression, decreased concentration, decreased motivation for socializing and daily activities, autonomic nervous system disorders, pain, poor control, and decreased quality of sleep, the amount of Rhaematous ulcerative colitis leaf extract is preferably 30 mg to 150 mg, more preferably 35 mg to 125 mg, and most certainly 40 to 100 mg / day.

[0028] Furthermore, the Rahmannia leaf extract in this composition contains the flavonoid compounds hyperoside and isoquercitrin as active ingredients, and the effects of this composition are best exhibited by containing these compounds in a total amount of preferably 4% by weight or more, and more preferably in the range of 4% by weight to 10% by weight.

[0029] The present composition has the effect of improving menstrual symptoms such as unspecified complaints, depression, decreased concentration, decreased motivation for socializing and daily activities, autonomic nervous system disorders, pain, poor control, and poor quality of sleep. The range in which this effect can be obtained will become clear from the examples described below, but is the same as above.

[0030] As described above, the present invention provides a composition that improves menstrual symptoms such as vague symptoms, depression, decreased concentration, decreased motivation for socializing and daily activities, autonomic nervous system disorders, pain, control, and decreased quality of sleep.

[0031] Example 1 Here, the composition according to the above embodiment was actually produced, and its effects were confirmed. Specific explanations are given below.

[0032] (1) Preparation of Rahmania leaf extract: Dried Rahmania leaves were pulverized in a lab mixer, and 1 kg of the pulverized material was added to 6 L of 60% ethanol for extraction. The extract was then filtered to obtain an extract. The extraction residue was then extracted again with 6 L of 60% ethanol and filtered to obtain an extract. The first and second extracts were combined, concentrated under reduced pressure at 60°C, adjusted to an acidic state, and passed through a synthetic adsorption resin to adsorb the active ingredient. The resin was then washed with water to remove carbohydrates and other substances. The fraction containing the active ingredient was then desorbed with aqueous ethanol, collected, concentrated under reduced pressure at 50°C, and dried to obtain 95 g of solid material.

[0033] Furthermore, when the solid obtained above was measured by liquid chromatography, it was confirmed that it contained 2 to 5% by weight of hyperoside and 2 to 5% by weight of isoquercitrin, for a total of 4 to 10% by weight.

[0034] (2) Clinical trials: In the clinical trials, tablets containing 25 mg of Rhafnia leaf extract were used. In addition, a food additive coloring agent was used instead of Rhafnia leaf extract to ensure the placebo had the same appearance as the test food.

[0035] A randomized, placebo-controlled, double-blind, parallel-group comparative study was conducted on 42 healthy adult women who were currently being treated for premenstrual syndrome or premenstrual dysphoric disorder or had no history of the condition, to examine the effects on menstrual complaints, sleep, and other symptoms. The test food was taken from seven days after the first day of their first menstrual period to seven days after the first day of their next menstrual period (one menstrual cycle). The intervention group took 50 mg of Rhaematocele leaf extract per day, and the placebo group took placebo tablets of the same number of tablets.

[0036] The Japanese version of the Menstrual Distress Questionnaire (MDQ), which evaluates subjective symptoms related to menstrual complaints, was used to evaluate subjective symptoms before and during menstruation before and after intake. The total score for menstrual complaints and eight subscales (pain, fluid retention, autonomic nervous system, negative emotions, concentration, behavioral changes, mood elevation, and control) were evaluated on a 5-point scale (4 points: very strong / very strong symptoms, 3 points: strong / strong symptoms, 2 points: slight / slight symptoms, 1 point: slight / slight symptoms, 0 point: no symptoms at all). The higher the score, the greater the severity of the discomfort.

[0037] Furthermore, the OSA Sleep Questionnaire MA version was used to evaluate the perceived improvement in sleep before and after intake. The higher the score, the better the sleep quality.

[0038] Clinical trial results (1) MDQ total score (menstrual complaints) In the MDQ total score, which evaluates menstrual complaints, significant improvements were observed in the intervention group compared to the placebo group before and during menstruation after intake (P<0.05).

[0039] (2) Subscale “Concentration” In the subscale “concentration,” which evaluates vague symptoms associated with menstruation, the intervention group showed significant improvement compared to the placebo group before and during menstruation after intake (P<0.05).

[0040] (3) Subscale “Negative Affect (Depressed Mood)” In the subscale “Negative Affect (Depressed Mood),” which evaluates vague symptoms associated with menstruation, the intervention group showed significant improvement compared to the placebo group before menstruation after intake (P<0.05).

[0041] (4) Subscale “Behavioral Change (Motivation to Socialize and Participate in Daily Activities)” In the subscale “Behavioral Change (Motivation to Socialize and Participate in Daily Activities)” which evaluates vague symptoms associated with menstruation, the intervention group showed significant improvement compared to the placebo group before menstruation after intake (P<0.05).

[0042] (5) Subscale “Autonomic Nervous System” In the subscale “Autonomic Nervous System” that evaluates vague symptoms associated with menstruation, the intervention group showed significant improvement compared to the placebo group before menstruation after intake (P<0.05).

[0043] (6) Subscale “Pain” In the subscale “Pain” which evaluates vague symptoms associated with menstruation, the intervention group showed significant improvement during menstruation after intake compared to the placebo group (P<0.05).

[0044] (7) Subscale “Control” In the subscale “Control” that evaluates vague symptoms associated with menstruation, the intervention group showed significant improvement compared to the placebo group during menstruation after intake (P<0.05).

[0045] (8) Results of the MA version of the OSA Sleep Questionnaire In factor II, which evaluates sleep onset and sleep maintenance, significant improvement was observed in the intervention group compared to the placebo group before menstruation after intake (P<0.05).

[0046] As mentioned above, the above human trials have confirmed that the compound has the effect of improving menstrual symptoms such as depression, decreased concentration, decreased motivation for socializing and daily activities, autonomic nervous system disorders, pain, poor control, and poor quality of sleep.

Claims

1. A composition for improving vague symptoms before and during menstruation, containing Rahmannia leaf extract as an active ingredient.

2. A composition for improving vague symptoms before and during menstruation as described in claim 1, wherein the Rahmannia leaf extract contains 4 to 10% by weight in total of the flavonoid compounds hyperoside and isoquercitrin.

3. A composition for improving vague symptoms before and during menstruation according to claim 1, wherein the daily intake amount of the Rhagnia leaf extract is in the range of 40 mg to 100 mg.

4. A composition containing Rahmannia leaf extract as an active ingredient that improves loss of concentration before and during menstruation.

5. A composition for improving decreased concentration before and during menstruation as described in claim 4, wherein the Rahmannia leaf extract contains 4 to 10% by weight in total of the flavonoid compounds hyperoside and isoquercitrin.

6. A composition for improving decreased concentration before and during menstruation according to claim 4, wherein the daily intake amount of the Rhagnia leaf extract is in the range of 40 mg to 100 mg.

7. A composition containing Rahmannia leaf extract as an active ingredient for improving premenstrual depression.

8. A composition for improving premenstrual depression according to claim 7, wherein the Rahmannia leaf extract contains 4 to 10% by weight in total of hyperoside and isoquercitrin, which are flavonoid compounds.

9. A composition for improving premenstrual depression according to claim 7, wherein the daily intake of the Rhagnia leaf extract is in the range of 40 mg to 100 mg.

10. A composition containing Rahmannia leaf extract as an active ingredient that improves premenstrual decline in motivation for social interaction and daily activities.

11. The composition for improving premenstrual loss of motivation for social interactions and daily activities according to claim 10, wherein the Rahmannia leaf extract contains 4 to 10% by weight in total of the flavonoid compounds hyperoside and isoquercitrin.

12. A composition for improving premenstrual decline in motivation for social interaction and daily activities as described in claim 10, wherein the daily intake amount of the Rhagnia leaf extract is in the range of 40 mg to 100 mg.

13. A composition containing Rahmannia leaf extract as an active ingredient for improving premenstrual autonomic nervous system disorders.

14. A composition for improving premenstrual autonomic nervous disorders as described in claim 13, wherein the Rahmannia leaf extract contains 4 to 10% by weight in total of the flavonoid compounds hyperoside and isoquercitrin.

15. A composition for improving premenstrual autonomic nervous system disorders as described in claim 13, wherein the daily intake amount of the Rhagnia leaf extract is in the range of 40 mg to 100 mg.

16. A composition containing Rahmannia leaf extract as an active ingredient for relieving menstrual pain.

17. A composition for alleviating menstrual pain as described in claim 16, wherein the Rahmannia leaf extract contains 4 to 10% by weight in total of the flavonoid compounds hyperoside and isoquercitrin.

18. A composition for alleviating menstrual pain as described in claim 16, wherein the daily intake amount of the Rahmania leaf extract is in the range of 40 mg to 100 mg.

19. A composition for improving menstrual control containing Rahmannia leaf extract as an active ingredient.

20. A composition for improving menstrual control as described in claim 19, wherein the Rahmannia leaf extract contains 4 to 10% by weight in total of the flavonoid compounds hyperoside and isoquercitrin.

21. A composition for improving menstrual control as described in claim 19, wherein the daily intake amount of the Rahmania leaf extract is in the range of 40 mg to 100 mg.

22. A composition for improving premenstrual sleep containing Rahmannia leaf extract as an active ingredient.

23. A composition for improving premenstrual sleep as recited in claim 22, wherein the Rahmannia leaf extract contains 4 to 10% by weight in total of the flavonoid compounds hyperoside and isoquercitrin.

24. A composition for improving premenstrual sleep as described in claim 22, wherein the daily intake amount of the Rhagonia leaf extract is in the range of 40 mg to 100 mg.

Citation Information

Patent Citations

  • Composition for maintaining and improving falling-asleep and sleep, composition for reducing stress and improving relaxing, composition for improving performance and concentration, and composition for improving rest and recovering from fatigue

    JP2019064969A